Introduction
Metastasis is the major cause of death in cancer patients. The spread of tumor cells from a primary tumor to secondary sites within the body is complex, involving processes such as migration, invasion, adhesion, proliferation and angiogenesis. A primary challenge of cancer biologists is to develop improved methods to predict metastatic potential of tumor cells. One approach to address this challenge may involve the identi®cation of the genetic events controlling metastasis, which are not completely understood (Kohn, 1993) . Metastasis suppressor genes, which are functionally inactivated as tumor cells acquire metastatic ability, may have signi®cant prognostic value as markers of tumor metastatic potential. Mutations in metastasis suppressor genes or downregulation of the their expression could indicate which tumors may metastasize. Several metastasis suppressor genes have been mapped, but only a few cloned to date (Dear and Keord, 1990; Dong et al., 1996) .
Recently, we reported that the KAI1 gene, located on human chromosome 11p11.2, is a metastasis suppressor gene for prostate cancer (Dong et al., 1995) . When transfected into the highly metastatic Dunning rat subline AT6.1, KAI1 signi®cantly reduces the metastatic ability of the rat cells. The study also showed that KAI1 mRNA expression is downregulated in human cell lines derived from prostate cancer metastases when compared to normal prostate cells, suggesting a suppressor role for KAI1 in human prostate cancer. KAI1 is ubiquitously expressed by human lymphoid and epithelial cells, and also is expressed by some ®broblasts (Dong et al., 1995; Fukudome et al., 1992) . Therefore, it is possible that KAI1 is a metastasis suppressor gene for dierent types of human cancers.
The potential importance of KAI1 as a metastasis suppressor gene has been implicated in three human cancers; prostatic, non-small cell lung, and pancreatic carcinomas. Advanced prostate tumors show reduced KAI1 expression compared to normal prostate and benign prostatic hyperplasia, and the downregulation does not involve mutation or allelic loss of KAI1 (Dong et al., 1996) . Both Gleason grade and clinical stage of prostate cancers have an inverse correlation with the percentage of KAI1 positive cancer cells (Ueda et al., 1996) . Prostate cancers with higher Gleason grades or that are more advanced clinically have reduced levels of KAI1 expression. Additionally, with non-small cell lung cancers, the survival rate of patients with KAI1-positive cancer was signi®cantly higher than the survival rate of patients with KAI1-negative cancer (Adachi et al., 1996) . Finally, advanced pancreatic tumor stages, in which metastases are present, have reduced KAI1 mRNA levels compared with earlier pancreatic tumor stages (Guo et al., 1996) . KAI1 protein is a member of the transmembrane four superfamily (TM4SF) (Gaugitsch et al., 1991) . There are at least 15 TM4SF proteins. Members of the TM4SF are cell membrane proteins that contain four hydrophobic, presumably transmembrane, domains and one large extracellular, hydrophilic domain that often contains potential N-linked glycosylation sites. KAI1 is identical to the previously characterized antigens R2, IA4, C33 and 4F9 and is designated CD82 by the clusters of dierentiation (CD) nomenclature (Engel and Tedder, 1994) . KAI1(CD82) contains three potential N-linked glycosylation sites and is a glycoprotein (Dong et al., 1995; Fukudome et al., 1992; Lebel-Binay et al., 1994; Nojima et al., 1993) . TM4SF proteins associate with each other and with other proteins such as CD4, CD8, Leu-13, CD19, CD20 and integrins (Angelisova et al., 1994; Berditchevski et al., 1996; Rubinstein et al., 1996; . KAI1 associates with CD81 in human B cell and T cell lines (Imai and Yoshie, 1993) and associates with HLA class I heavy chain and MHC I in various B cell lines (Lagaudriere et al., 1997) . The physiological roles of TM4SF proteins are largely unknown, but the proteins are implicated in signal transduction, cell-cell interactions, and cell-extracellular matrix interactions. These putative functions are consistent with a role in malignancy.
Three other TM4SF proteins, in addition to KAI1, are associated with malignancy. Antibodies against CD81(TAPA1) induce an antiproliferative eect on some lymphoma and leukemia cell lines (Oren et al., 1990) . CD9(MRP-1) inhibits cell motility in Chinese hamster ovary cells, MAC10 human lung adenocarcinoma cells, and ARH77 human myeloma cells (Miyake et al., 1991) and reduces metastasis in BL6 mouse melanoma cells (Ikeyama et al., 1993) . Low CD9 expression correlates with breast cancer metastasis (Miyake et al., 1995) . A study of skin-super®cial spreading melanomas and metastatic melanomas showed that CD63(ME491) expression associates with early stages of melanoma progression and reduced expression in advanced stages of melanoma (Atkinson et al., 1985) .
In this study, we used Western blot analysis to evaluate KAI1 protein expression in multiple types of human cancer cell lines and their respective normal cells as an initial study to determine if KAI1 may be involved in the malignant progression of dierent types of cancer. Furthermore, we determined the relationship of KAI1, CD81 and CD9 protein expression in the cancer cell lines. Established cell lines are unique tools for studying malignancy but also have limitations due to selection of cells in vitro. Nevertheless, human cancer in culture is the starting point for much of current cancer research. The majority of cells in tumor-derived cell lines maintain the dierentiated state of the original tumor (Fusenig et al., 1991) . Analyses of KAI1 expression in prostate tumors and prostate tumor-derived cell lines have shown similarities; in both instances, KAI1 downregulation associates with advanced stage tumors (Dong et al., 1995 (Dong et al., , 1996 Ueda et al., 1996) . We found that KAI1 protein expression is reduced in most of the cancer cell lines we examined in comparison to normal cells. Additionally, normal ovarian and bladder cells and some ovarian, bladder and endometrial carcinoma cell lines have KAI1 protein with distinct, heterogeneous protein band patterns in Western blots that are most likely due to N-linked glycosylation. The majority of the cancer cell lines have normal CD81 and CD9 protein expression with downregulated KAI1 expression. Collectively, these data suggest that KAI1 downregulation may occur frequently and independently of related TM4SF proteins in malignant progression of various types of human tumors and that the protein may contain posttranslational modi®cations speci®c to tissue type or malignant progression. The prognostic value of KAI1 in cancers of urogenital and gynecological origin and malignant melanomas should be investigated to address the role of KAI1 in these cancers. (Figure 1a ). The TSU-Prl carcinoma cells had KAI1 protein that was comparable in apparent molecular weight to the protein in normal prostate cells. The level of KAI1 protein was slightly reduced in TSU-1 cells compared to normal prostate gene epithelial cells. However, signi®cant downregulation (loss of detectable expression) of KAI1 protein occurred in three of the four prostate carcinoma cell lines ( Figure 1a , Table 1 ). KAI1 RNA expression as measured by reverse transcriptase polymerase chain reaction analysis in the prostate carcinoma cell lines, and the other types of cancer cell lines that will be described, was consistent with KAI1 protein expression (data not shown). Immuno¯uorescence staining for KAI1 in the normal prostate cells and TSU-Pr1 cells showed cell membrane speci®c staining for KAI1. The cell staining was heterogeneous and some subclones of TSU-Pr1 were positive for KAI1 expression and others were negative (data not shown).
Results

KAI1
We removed N-linked oligosaccharides from cellular proteins using N-glycanase to determine the contribution of N-linked glycosylation to the KAI1 molecular weight. KAI1 protein in PrEC 4428 cells was a 28 kD band after removal of N-linked oligosaccharides ( Figure 1b) . The 28 kD, deglycosylated KAI1 protein is consistent with the predicted molecular weight of KAI1 based upon its amino acid sequence (Dong et al., 1995) and indicates that the broad molecular weight (Figure 1c) . In all the cancer cell types analysed in this study with detectable KAI1 expression, deglycosylated KAI1 protein was 28 kD (data not shown).
KAI1 protein in malignant melanoma cell lines
Normal human melanocytes, NHEM 2486, contained the highest level of KAI1 protein of all the normal cells analysed (Figure 2a) . However, the KAI1 protein still ranged between 46 and 60 kD. All ®ve of the melanoma cell lines examined originated from metastases and all had decreased levels of KAI1 protein compared to the normal melanocytes ( Figure 2a , Table 1 ).
KAI1 protein in ovarian carcinoma cell lines
KAI1 protein in normal ovarian tissue was unique compared to the other normal cells examined. The protein was a discreet band at 45 kD (Figure 2b ). KAI1 protein in SK-OV-3 ovarian carcinoma cells was also a discreet 45 kD band (data not shown), but it was detected only after extended exposure of the ECL TM reaction to X-ray ®lm because the protein expression was downregulated. In stark contrast to the normal cells, some of ovarian carcinoma cell lines had heterogeneous KAI1 protein patterns ranging from 35 ± 60 kD. Half (3/6) of the ovarian carcinoma cell lines had downregulated KAI1 protein ( Figure 2b , Table 1 ).
KAI1 protein in bladder carcinoma cell lines
The KAI1 protein pattern also diered in normal bladder cells compared to the other normal cells analysed, although the size range of KAI1 protein was similar, 46 ± 60 kD (Figure 2c ). The normal bladder cell KAI1 protein pattern consisted of two distinct series of bands instead of the continuous smear that was observed in normal prostate cells and melanocytes. At least 90% of malignant bladder tumors are transitional cell carcinomas (Kakizoe et al., 1995) . We analysed KAI1 protein in seven cell lines derived from transitional cell carcinomas and one cell line derived from a transitional cell papilloma, RT-4. KAI1 protein was downregulated in 38% (3/8) of the bladder cell lines (Figure 2c , Table 1 ). The TCC-SUP cell line had increased KAI1 protein expression compared to normal bladder cells. The KAI1 protein pattern in half of the carcinoma cell lines had an additional band at about 40 kD (Figure 2c ). A representative Western blot for actin protein ( Figure  2d ) showed consistent loading of protein from the dierent cell lines.
KAI1 protein in endometrial carcinoma cell lines
KAI1 protein in normal endometrial cells was similar to the protein in normal prostate epithelial cells ( Figure  3a) . Normal endometrial epithelial cells were not available for analysis. The endometrial carcinoma cell lines originated from adenocarcinomas, with the exception of the ANC3A cell line, which was derived from a lymph node metastasis (Table 1) . KAI1 protein was downregulated in 88% (7/8) of the carcinoma cell lines compared to the normal endometrial cells. The HHOUA, Ishikawa and KLE cells had the same molecular weight KAI1 protein pattern, 50 ± 70 kD, although they were derived from tumors in dierent patients (Figure 3a) . One exception to the consistent correlation between KAI1 RNA and protein expression was the HEC59 endometrial carcinoma cell line. KAI1 RNA was present in HEC59 cells (data not shown), but KAI1 protein was absent Figure 3 .
KAI1 protein in lung carcinoma cell lines
We assessed KAI1 protein in three dierent types of normal human lung cells and eleven cell lines derived from non-small cell lung cancers. The normal cells were mucosal epithelial cells, squamous epithelial cells, and WI38 embryonic ®broblasts. The normal mucosal cells expressed half the level of KAI1 protein expressed in normal squamous cells (Figure 3b ). The normal mucosal cells were a control for the 1848 cancer cell line. Both the normal mucosal cells and the 1848 cell line had KAI1 protein that was 50 ± 60 kD. The normal squamous cells and WI38 ®broblasts had similar KAI1 protein expression, 46 ± 60 kD, and were controls for the rest of the lung cancer cell lines (Figure 3b and c) . KAI1 protein was downregulated in 80% (4/5) of cell lines derived from primary lung tumors and in 100% (6/6) of the cell lines derived from metastatic lung cells (Figure 3c , Table 1 ).
CD9 and CD81 proteins in the cancer cell lines
Western blot analysis of two KAI1-related proteins, CD81 and CD9, was evaluated to determine any potential correlation with KAI1 protein in malignant progression. CD81 protein is not a glycoprotein (Oren et al., 1990) and had an apparent molecular weight of 24 kD in the normal cells and cancer cell lines (Figures  2c and 3c) . Of the four possible relationships between KAI1 and CD81 expression in the cancer cell lines, the most prevalent correlation, 52% (22/42), was downregulated KAI1 expression and normal CD81 protein expression (Table 1) . Both KAI1 and CD81 had normal expression in 24% (10/42) of the cancer cell lines, whereas both proteins were at reduced levels in 21% (9/42) of the cell lines. Only one cell line, T24, had normal KAI1 protein expression and reduced levels of CD81 protein (Figure 2c , Table 1 ). Also the majority of the cancer cell lines, 50% (21/ 42), had downregulated KAI1 protein and normal CD9 protein expression (Table 1) . CD9 is a glycoprotein (Miyake et al., 1995) and our Western blots showed two protein bands at 25 and 28 KD (Figures 1a and 3c) . In our analyses, the 25 kD protein band was usually more intense than the 28 kD band, and after protein deglycosylation only the 25 kD band was detected (data not shown). The combination of downregulated KAI1 and CD9 proteins was found in 24% (10/42) of the cancer cell lines, and normal expression of both proteins was found in 19% (8/42) of the cells. Only three cell lines, J82, T24, and PA-1, had normal KAI1 protein expression and reduced CD9 protein.
Of the eight possible expression combinations of KAI1, CD81 and CD9 proteins, the most prevalent, 36% (15/42), was downregulated KAI1 expression and normal expression of CD81 and CD9. Of the cancer cell lines examined 19% (8/42) had normal expression of all three TM4SF proteins, whereas about 10% (4/42) of the cell lines had reduced expression of all three proteins. All of the other possible expression combinations were found in the cancer cell lines, except for the combination of normal KAI1 and CD9 protein expression and reduced CD81 expression. Four of the cancer cell lines analysed, HTB183, Gupton, NZM1, and NZM2, contained reduced levels for all three TM4SF proteins (Table 1) . Actin protein in those four cell lines was equivalent to positive controls (Figure 2d ).
Discussion
As a metastasis suppressor protein, KAI1 could be functionally inactivated by mutation, downregulation, post-translational modi®cation, or altered interactions with associated proteins in tumor cells as they become metastatic. This study shows that KAI1 protein expression is frequently downregulated in various types of human cancer cell lines. Reduced KAI1 protein was observed in 75% of prostate, 50% of ovarian, 38% of bladder, 88% of endometrial and 91% of lung carcinoma-derived cell lines and 100% of the malignant melanoma-derived cell lines we examined. Our results with the cancer cell lines are consistent with published data on KAI1 protein expression in human prostate and lung tumors. Advanced human prostate tumors have reduced KAI1 protein levels (Dong et al., 1996; Ueda et al., 1996) and nearly 80% of primary, non-small cell lung cancers had reduced KAI1 protein levels in a recent study (Adachi et al., 1996) . Downregulation of KAI1 occurs primarily at the transcriptional level. RNA and protein expression data directly correlates in the cancer cell lines with the exception of the HEC59 cell line, which has normal KAI1 RNA expression but reduced protein expression. In addition, KAI1 protein levels in the prostate cancer cell lines we analysed directly correlated with previously reported KAI1 mRNA levels in those cell lines (Dong et al., 1995) . KAI1 downregulation may be important in the malignant progression of various solid tissue-derived tumors.
KAI1 may be a useful target to study the eect of speci®c N-linked glycosylation alterations on metastatic potential. We know that KAI1 is a glycoprotein from studies of the protein in other contexts, C33, IA4 and 4F9 antigens, mainly in lymphocytes (Fukudome et al., 1992; Lebel-Binay et al., 1994; Nojima et al., 1993) . The heterogeneous molecular weight, 42 ± 100 kD, of KAI1 in normal and malignant B and T cells is attributed to N-linked glycosylation in those studies. KAI1 in normal and cancer cells in our study is within the size range reported for lymphocytes and N-linked deglycosylation of KAI1 indicates that the size range is due primarily to N-linked glycosylation. We show that KAI1 protein in melanocytes and normal cells of the prostate, ovary, bladder, endometrium, and lung has similar, heterogeneous molecular weights, 46 ± 60 kD. However, normal ovarian and bladder cells have KAI1 protein band patterns that suggests tissue speci®c modi®cations in glycosylation. Two normal cell strains we analysed, human prostate ®broblasts and umbilical vein endothelial cells (HUVEC), have no detectable KAI1 protein (data not shown). Furthermore, some of the ovarian, bladder, and endometrial carcinoma cell lines have more heterogeneous molecular weights than their normal counterparts. Whether the increased heterogeneity in KAI1 molecular weight is a consequence of or antecedent to malignancy remains to be determined. Increased b136 branched, complex, N-linked oligosaccharides in malignant cells is common and directly associates with metastatic potential, and accordingly, inhibition of N-linked glycosylation associates with decreased cell invasion and metastasis (Dennis, 1991) . We did not address speci®c oligosaccharide structural features of KAI1 in this study, but such studies in normal and cancer cells are in progress. KAI1-related TM4SF proteins CD81 and CD9 are expressed in the majority of the cancer cell lines assayed, in contrast to KAI1 protein. The most common expression combination of the three proteins is downregulated KAI1 and normal expression of CD81 and CD9. Compared to only 26% (11/42) of the cancer cell lines with normal KAI1 expression, 76% (32/42) of the cell lines have normal CD81 expression, and 69% (29/ 42) of the cell lines have normal CD9 expression. These results support studies in which CD81 and CD9 expression are detected in cell lines derived from carcinoma, sarcoma, and melanoma cells (Berditchevski et al., 1996; Oren et al., 1990) and another study that indicated CD9 is expressed on almost all human solid tumor cell lines (Miyake et al., 1991) . However, the expression arrangement among the three proteins is variable in the cell lines we examined, which implies that co-regulation of the three proteins is unlikely.
This study did not address whether KAI1 protein expression in the cancer cell lines correlates with invasion (in vitro) or spontaneous metastasis (in vivo). In vitro invasion assays using tumor cell lines and their relevance to metastatic human tumors is open to question, and a review of the literature indicates that most malignant human tumor cell lines are not metastatic in experimental systems (Sharkey and Fogh, 1979) . Perhaps the best way to establish a correlation between metastatic potential and KAI1 expression is through retrospective studies with normal and benign tissues, primary tumors, and matched metastases.
We think downregulation of KAI1 signi®es that a tumor cell can metastasize and thus KAI1 may be a potential prognostic marker. Allelic loss and mutation rarely occur in the KAI1 gene in prostate carcinomas (Dong et al., 1996) . So, it is probable that KAI1 mutations may not occur frequently in other cancer types. Therefore, studies that focus on KAI1 downregulation and glycosylation alterations may be most informative concerning the value of KAI1 as a prognostic marker. In particular, our results suggest that the role of KAI1 in malignant progression of gynecological and other urogenital cancers and malignant melanomas should be investigated along with ongoing studies of prostatic, lung and pancreatic cancers. In a current study, we are analysing KAI1 protein expression in human breast cancer cell lines, primary breast tumors, and breast cancer metastases. Preliminary results have shown KAI1 downregulation in some breast tumors and alterations in the KAI1 protein pattern in other breast tumors. Primary ovarian tumors have been analysed for KAI1 protein expression, and heterogeneous KAI1 protein patterns spanning a wide molecular weight range were observed in Western blots.
Materials and methods
Cells and culture conditions
All cells were of human origin and were maintained in a 378C humidi®ed chamber with 5% CO 2 . The cells grew in DMEM/Ham's F12 medium (1:1) (Gibco BRL) supplemented with 10% fetal bovine serum (Summit), unless noted otherwise. Normal prostate epithelial cells, PrEC 4428 (Clonetics), grew in PrEGM Bulletkit (Clonetics). PZHPV7, an HPV18-immortalized prostate epithelial cell line, was a generous gift from Dr Donna Peehl (Stanford University School of Medicine) and grew in KSFM (Gibco BRL) supplemented with 5 ng/ml EGF and 50 mg/ml bovine pituitary extract (Gibco BRL). Dr Carrie RinkerSchaeer (University of Chicago) provided TSU-Pr1 prostate carcinoma cells. Dr Cliord Rinehart (University of North Carolina at Chapel Hill) provided normal endometrial ®broblasts, 96 ± 0027. Normal human melanoctyes, NHEM 2486 (Clonetics), grew in MGM-3 Bulletkit (Clonetics). Dr Anton Jetten (National Institute of Environmental Health Sciences) provided normal squamous lung epithelial cells and normal mucosal lung epithelial cells. Dr Bruce Baguley (University of Auckland School of Medicine, Auckland, New Zealand) provided malignant melanoma cell lines NZM1, NZM2, NZM3, and NZM4 that grew in aMEM (Gibco BRL) supplemented with 10% fetal bovine serum. Cell lines contributed by Dr H Sasaki (Jikei University School of Medicine, Tokyo, Japan) included BG-1, HEC59, HHOUA, HHUA and Ishikawa. We obtained all other cell lines from the American Type Culture Collection (ATCC, Rockville, Maryland). Lung carcinoma cell lines were cultured in media speci®ed by the ATCC. Dr Jack Taylor (National Institute of Environmental Health Sciences) kindly provided frozen, normal human bladder tissue.
Western blot analysis
The Western blot protocol used was previously described (Fukudome et al., 1992) . Brie¯y, cell proteins were solubilized in lysis buer (10 mM Tris pH 8.0, 150 mM NaCl, 3 mM MgCl 2 , 0.5% NP ± 40, 2 mM phenylmethylsulfonly¯uoride) when cell cultures reached 50 ± 90% con¯uence. The proteins were normalized to 1 mg/ml, mixed with an equal volume of Laemmli's sample buer without 2-mercaptoethanol, and boiled for 3 min. After SDS-polyacrylamide gel electrophoresis (17.5%) of 40 mg total protein per cell line, proteins were electrophoretically transferred to Immobilon-P (Millipore) membrane. Membranes were stained with Ponceau S (Sigma) to assess equal loading of proteins. We used C33 hybridoma supernatant (Dr Osamu Yoshie, Shionogi Institute for Medical Science, Osaka, Japan) to detect KAI1 protein, 5A6 antibody (Dr Shoshana Levy, Stanford University) to detect CD81 (TAPA1) protein, and CD9 antibody (Serotec) to detect CD9(MRP-1) protein. The ECL TM Western blotting analysis system (Amersham) detected bound antibody. Protein from normal human ovary was provided by Dr Bernard Weissman (University of North Carolina at Chapel Hill). Each cell line was assayed in three independent experiments. Densitometer readings of the protein were made, and reduced expression was scored as cell lines with a reproducible 4twofold decrease in expression of all forms of the protein.
Protein deglycosylation
We used N-glycanase (Genzyme) and the protocol recommended by the manufacturer to remove N-linked oligosaccharides from proteins. In the protocol, proteins were incubated with enzyme in the presence of 5% NP-40 overnight. Enzyme-treated proteins were mixed with sample buer and analysed by Western blotting as described.
